At RNhale, our mission is to unlock the potential of RNA therapeutics for severe respiratory diseases by enabling local delivery directly to the lungs – the point of action. Conditions such as COPD, severe persistent asthma, viral infections, and pulmonary fibrosis urgently need innovative treatments that are both effective and accessible. That is why we developed dry-powder RNA formulations that are stable at room temperature, require no cold chain logistics, and can be administered via dry powder inhalers that require no external power source or propellant gas but are actuated by the patient.. Our approach will help make cutting-edge therapies globally accessible, even in regions with limited infrastructure. With our proprietary technology, we are rethinking what is possible respiratory care.